said Monday that it was issued U.S. patent number 7,118,892, which extends the company's intellectual property estate relating to integrated instrument systems for nucleic acid testing.
The newly issued patent claims relate to automated processes for isolating, purifying and amplifying target nucleic acid sequences in a stand-alone unit, the San Diego-based company said.
"This important new patent extends what was already a strong intellectual property estate surrounding automated instrumentation for molecular diagnostics, and recognizes our pioneering role in the field," the company said. "Our proprietary automation technologies have helped deliver highly sensitive molecular diagnostics techniques to clinical and blood testing laboratories, where medical technologists are in short supply."
This story was created through a joint venture between TheStreet.com and IRIS.